Latest news with #HighContentScreening
Globe and Mail
3 days ago
- Business
- Globe and Mail
High Content Screening Market worth US$2.19 billion in 2030 with 7.5% CAGR
"The prominent players operating in the high content screening market are Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Merck KGaA (Germany), and Thermo Fisher Scientific, Inc. (US), among others." Browse 363 market data Tables and 31 Figures spread through 358 Pages and in-depth TOC on "High Content Screening Market by Product & Services (Instrument (Cell Imaging, Analysis System), Consumables (Reagents & Assay Kits, Microplates), Software), Application (Drug Discovery & Development, Toxicology), End User - Global Forecast to 2030 The global High Content Screening Market, valued at US$1.47 billion in 2024, is forecasted to grow at a robust CAGR of 7.5%, reaching US$1.52 billion in 2025 and an impressive US$2.19 billion by 2030. Al and machine learning advancements enhance image analysis capabilities, improving the accuracy and efficiency of high-throughput screening. The expanding applications of HCS in personalized medicine, oncology research, and cell- based assays contribute to market growth. Furthermore, government funding for cell-based research and the rising prevalence of chronic diseases are increasing the adoption of HCS technologies across various research fields. Key segments positively impacting the market include high-content imaging platforms, which dominate due to their critical role in drug discovery and cellular research. Among applications, drug discovery and development lead the market, with pharmaceutical and biotechnology companies being the largest end users due to their extensive R&D investments. The rising adoption of toxicology screening and target identification further supports market growth. Browse in-depth TOC on " High Content Screening Market" 363 - Tables 31 - Figures 358 - Pages By Based on cell detection and analysis system segment, the market is segmented by instrument into high content imaging platforms, cell detection and analysis systems, and cell imaging systems. The high content imaging platforms segment dominated the market in 2024. High content imaging platforms hold a significant share in the market owing to their critical role in cellular analysis, drug discovery, and phenotypic screening. These platforms enable high-throughput imaging of live and fixed cells, providing detailed cellular morphology and functional insights necessary for drug screening, toxicity assessment, and disease modelling. By Based on Primary and Secondary screening, the application segment is divided into drug discovery & development applications, toxicology, and basic research. The drug discovery & development application segment is further divided into primary screening and secondary screening, target identification and validation, compound profiling, and other drug discovery & development applications. The rising focus on precision medicine, personalized therapies, and high-throughput screening applications has reinforced the demand for high content imaging systems in research and clinical settings. By Based on end user, the market is segmented into pharmaceutical & biotechnology companies, academic & government institutes, and CROs & CDMOs. pharmaceutical & biotechnology companies dominated the segment in 2024 and is anticipated to grow at the highest CAGR during the forecast period of 2025-2030. Dominance of the segment is attributable to increasing complexity of drug candidates, particularly in oncology, immunology, and neurological disorders, which has further boosted the demand for HCS in cellular imaging and phenotypic screening. Moreover, the growing trend of precision medicine and biologics development also contributes to the increased utilization of HCS technologies, which is supporting the segment growth in high content screening market. By geography, the high content screening market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the market due to a strong presence of leading academic institutions and market players, substantial investments in biotechnology and pharmaceutical research, and advanced healthcare infrastructure. Asia-Pacific (APAC) is witnessing rapid growth, due to the rising prevalence of chronic diseases, increasing healthcare investments, and expanding research capabilities. Countries like China, India, and Japan are experiencing substantial advancements in biotechnology and drug discovery, supporting to the growing demand for high content screening technologies. Request Sample Pages: The prominent players operating in the high content screening market are Danaher Corporation (US), Revvity, Inc. (US), BD (US), Carl Zeiss AG (Germany), Merck KGaA (Germany), and Thermo Fisher Scientific, Inc. (US), among others. Danaher (US) is one of the leading players in the high content screening market. The company has a presence in more than 60 countries and offers a diversified product portfolio of instruments and software in the high content screening market. Danaher strongly focuses on organic and inorganic growth strategies to maintain a dominant position in the market. The company operates in the market through Beckman Coulter, Molecular Devices, and Integrated DNA Technologies, among others. Danaher's robust global distribution network and dedicated customer support help the company to maintain its dominant position in the market. Revvity, Inc. (US) is one of the dominant players in the high content screening market. The company has a global presence in more than 150 countries and has diversified products for the high content screening market. The company's product offerings include instruments, software, and consumables such as automated cell counter, flow cytometer, microscope, cell imaging systems, and microplate readers. A robust global distribution network and customer-centric approach ensure Revvity serves diverse sectors, including academia, biotechnology, and pharmaceuticals. For more information, Inquire Now!
Yahoo
21-05-2025
- Business
- Yahoo
High Content Screening (HCS) Business Analysis Report 2025: Global Market to Reach $2.2 Billion by 2030 - Rising Investments in Biotechnology and Life Sciences Expands Scope
The global High Content Screening (HCS) market is forecast to grow from USD 1.3 billion in 2024 to USD 2.2 billion by 2030, driven by advancements in imaging and personalized medicine. HCS enhances drug discovery by enabling real-time cellular analysis, crucial for cancer research and therapeutic development. Key market segments include Instruments and Consumables with notable growth in regions like the U.S. and China. This report offers insights into market trends, drivers, regional performances, and competitive landscapes, aiding strategic business decisions. High Content Screening (HCS) Market Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "High Content Screening (HCS) - Global Strategic Business Report" report has been added to global market for High Content Screening (HCS) was valued at US$1.3 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing at a CAGR of 9.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the High Content Screening (HCS) market. High Content Screening (HCS) is revolutionizing the field of biological research and drug discovery by enabling detailed observations of cellular processes in real-time, particularly enhancing the development of personalized medicine. HCS utilizes advanced imaging and analysis techniques to study the effects of various compounds on cells, offering insights far beyond traditional methodologies that used isolated cells. This technique is becoming increasingly pivotal, especially with its application in living multicellular structures like organoids or tissue sections, which more accurately simulate biological interactions within organisms. This nuanced observation at the cellular level allows for a deeper understanding of the cellular dynamics that characterize health and disease states, pushing forward the boundaries of biomedical research and therapeutic the realm of cancer research, HCS has proven invaluable. Traditional models that cultivate tumor cells in artificial environments can induce unnatural behaviors; however, HCS addresses this by using environments that include an extracellular matrix, leading to more natural cellular behavior and responses. This setup allows for the creation of microtissues that closely mimic natural tumor environments, which are then tested against various drugs using automated microscopy and sophisticated image analysis. This phenotypic screening helps to personalize treatment by identifying how individual cells within a tumor respond to specific drugs, highlighting the variability in drug resistance and efficacy. This method significantly refines our understanding of cancer cell dynamics and is instrumental in crafting more effective and personalized treatment regimens, thus minimizing the trial-and-error often associated with cancer integration of HCS into clinical practice, however, faces significant challenges, primarily due to the complexities involved in maintaining accurate 3D cultures and the analysis of large datasets they generate. Despite these hurdles, technological advancements are facilitating the miniaturization of tissue-like structures suitable for high-throughput screening, enhancing the scalability of HCS applications. Key growth drivers for HCS include the integration with multicellular and 3D models, advancements in imaging technologies, and the development of automated analysis software. Additionally, the increasing emphasis on personalized medicine and the expansion of drug discovery efforts demand more effective screening technologies like HCS. Regulatory support for predictive models and consumer demand for quicker, more accurate testing methods also significantly contribute to the broader adoption and ongoing development of HCS, underscoring its growing impact on the fields of drug development and personalized ScopeKey Insights: Market Growth: Understand the significant growth trajectory of the Instruments segment, which is expected to reach US$1.0 Billion by 2030 with a CAGR of a 9.4%. The Consumables segment is also set to grow at 8.2% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $332.6 Million in 2024, and China, forecasted to grow at an impressive 12.3% CAGR to reach $492.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as BD Biosciences, BioTek Instruments Inc., EMD Millipore, Essen BioScience, Evotec AG and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Tariff Impact Analysis: Key Insights for 2025What's Included in This Edition: Tariff-adjusted market forecasts by region and segment Analysis of cost and supply chain implications by sourcing and trade exposure Strategic insights into geographic shifts Buyers receive a free July 2025 update with: Finalized tariff impacts and new trade agreement effects Updated projections reflecting global sourcing and cost shifts Expanded country-specific coverage across the industry Key Attributes: Report Attribute Details No. of Pages 183 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.3 Billion Forecasted Market Value (USD) by 2030 $2.2 Billion Compound Annual Growth Rate 9.2% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights Global Economic Update High Content Screening (HCS) - Global Key Competitors Percentage Market Share in 2024 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E) MARKET TRENDS & DRIVERS Rising Demand for Drug Discovery and Development Propels Growth in HCS Market Advances in Imaging Technologies Strengthen Business Case for High Content Screening Adoption Increasing Focus on Personalized Medicine Expands Addressable Market Opportunity for HCS Technological Innovations in Cell-Based Assays Drive Market Growth Growing Use of HCS in Genomics and Proteomics Accelerates Market Penetration Integration of AI and Machine Learning in HCS Throws the Spotlight on Enhanced Data Analysis and Prediction Rising Investment in Biotechnology and Life Sciences Expands Market Scope for HCS Solutions Advances in Miniaturization and Microfluidics Propel Development of High-Performance HCS Systems Focus on Reducing Drug Development Costs and Time-to-Market Spurt Demand for HCS Technologies Increasing Adoption of HCS in Academic and Research Institutions Development of Novel 3D Cell Cultures Expands Addressable Market Opportunity for HCS Advances in Fluorescence and High-Resolution Imaging Propel Growth in Precision Screening Applications Rising Demand for Toxicology Testing and Safety Assessment Drives Adoption of HCS Increasing Use of HCS in Stem Cell Research and Regenerative Medicine Expands Market Reach Development of User-Friendly and Scalable HCS Platforms Fuels Market Adoption Rising Importance of Target-Based and Phenotypic Screening Strengthens Business Case for HCS Growing Adoption of HCS in Cancer Research and Immuno-Oncology Expands Market Scope Focus on Enhancing Screening Efficiency and Throughput Drives Market Innovation FOCUS ON SELECT PLAYERS:Some of the 21 companies featured in this High Content Screening (HCS) market report include: BD Biosciences BioTek Instruments Inc. EMD Millipore Essen BioScience Evotec AG GE Healthcare Life Sciences Genedata AG IntelliCyt Corporation Molecular Devices Inc. PerkinElmer Inc. Thermo Fischer Scientific Inc. TTP LabTech Ltd. Yokogawa Electric Corporation For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment High Content Screening (HCS) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
